MedTrace Logo

Terlipressin in Combined Hepatorenal Syndrome in Patients With Signs of Chronic Renal Disease

NCT06161766 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 490

Last updated 2025-12-05

No results posted yet for this study

Summary

The aim of this retrospective study is to evaluate the treatment response to terlipressin and albumin in patients with suspicion of HRS-AKI and signs of chronic parenchymal kidney disease (HRS-AKI-like syndrome) compared to patients without signs of chronic parenchymal kidney disease (HRS-AKI).

Conditions

Interventions

DRUG

terlipressin or noradrenalin plus albumin

Patients with clinical suspicion of HRS-AKI or HRS-AKI-like syndrome in case of previously diagnosed CKD who had received vasoactive treatment for the management of HRS, as defined by the administration of terlipressin or noradrenalin plus albumin.

Sponsors & Collaborators

  • Jena University Hospital

    collaborator OTHER

  • Johannes Gutenberg University Mainz

    collaborator OTHER

  • University Hospital Muenster

    collaborator OTHER

  • University Hospital Freiburg

    lead OTHER

Principal Investigators

  • Cristina Ripoll, MD · University Hospital Jena

  • Dominik Bettinger, MD · University Hospital Freiburg

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-03
Primary Completion
2024-12-31
Completion
2024-12-31
FDA Drug
Yes

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06161766 on ClinicalTrials.gov